Bigul

Change in Registrar and Transfer Agent (RTA)

Lincoln Pharmaceuticals Ltd has informed BSE regarding "Change in Registrar and Transfer Agent (RTA)".
15-07-2016
Bigul

Updates

Lincoln Pharmaceuticals Ltd has informed BSE regarding "Audit Report in the matter of M/s. Sharepro Services (India) Private Ltd (R & T Agent of the Company)."
29-06-2016
Bigul

Board recommends Dividend

Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2016, has recommended the Dividend of Rs. 1/- (@10%) per Equity Share of face value of Rs. 10/- each.The meeting of the Board of Directors of the Company commenced at 11.45 a.m. and concluded at 1.05 p.m.
30-05-2016
Bigul

Standalone & Consolidated Financial Results, Form A, Auditors Report for March 31, 2016

Lincoln Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Form A for the period ended March 31, 20164. Consolidated Form A for the period ended March 31, 20165. Standalone Auditors Report for the period ended March 31, 20166. Consolidated Auditors Report for the period ended March 31, 2016
30-05-2016
Bigul

Board to consider Dividend

Lincoln Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2016, to consider and approve the Quarterly / Yearly Audited Financial Results for the aforesaid Quarter / Year end and to consider recommendation of Dividend, if any on the Equity Shares of the Company.In view of above, the trading window will remain close for the Promoters, Directors, Insiders, Designated Persons...
18-05-2016
Bigul

Shareholding for the Period Ended March 31, 2016

Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here
18-04-2016
Bigul

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016

Lincoln Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
15-04-2016
Bigul

Outcome of Board Meeting

Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 11, 2016, have considered and approved the following:1. Adoption of "Uniform Listing Agreement" as required to be entered by listed entity as per Regulation 109 of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009 read with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the...
11-02-2016
Bigul

Financial Results, Limited Review Report for December 31, 2015

Lincoln Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20152. Consolidated Financial Results for the period ended December 31, 20153. Standalone Limited Review for the period ended December 31, 2015
11-02-2016
Next Page
Close

Let's Open Free Demat Account